Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Mar;73(5):640–643. doi: 10.1038/bjc.1996.111

Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas.

P A Ellis 1, A Makris 1, S A Burton 1, J Titley 1, M G Ormerod 1, J Salter 1, T J Powles 1, I E Smith 1, M Dowsett 1
PMCID: PMC2074340  PMID: 8605100

Abstract

The MIB-1 antibody has been raised against recombinant parts of the Ki-67 antigen and, unlike Ki-67, has wider application to routinely fixed specimens. The aim of this study was to compare the usefulness of MIB-1 with S-phase fraction (SPF) as a measure of proliferation. A total of 75 patients with operable breast cancer were studied, 44 (median age 56 years) before any treatment and 31 (median age 68 years) after primary medical hormonal therapy. Sections from formalin-fixed paraffin-embedded tissue were stained with the MIB-1 antibody and a percentage score of positively stained cells obtained. SPF was measured by flow cytometry in fine-needle aspiration samples taken from the same lesion in each patient. Median MIB-1 score was 9% and median SPF was 11.1%. A close correlation was found between MIB-1 score and SPF (rho=0.59, P<0.0001). There was a difference in the strength of the correlation found between the no treatment group and the treatment group, however, 95% confidence intervals for the rho values overlapped, indicating that there was no significant statistical difference. When analysed for ploidy status a correlation was found only in aneuploid tumours. MIB-1 immunostaining can be used as an effective method of assessing proliferation in human breast carcinomas. This can be done using simple, widely available technology and provides the opportunity to perform large-scale retrospective analyses of archival materials.

Full text

PDF
640

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Camplejohn R. S., Ash C. M., Gillett C. E., Raikundalia B., Barnes D. M., Gregory W. M., Richards M. A., Millis R. R. The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Br J Cancer. 1995 Jan;71(1):140–145. doi: 10.1038/bjc.1995.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  3. Coombes R. C., Goss P., Dowsett M., Gazet J. C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1;2(8414):1237–1239. doi: 10.1016/s0140-6736(84)92795-8. [DOI] [PubMed] [Google Scholar]
  4. Dressler L. G., Seamer L. C., Owens M. A., Clark G. M., McGuire W. L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer. 1988 Feb 1;61(3):420–427. doi: 10.1002/1097-0142(19880201)61:3<420::aid-cncr2820610303>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  5. Fernando I. N., Titley J. C., Powles T. J., Dowsett M., Trott P. A., Ashley S. E., Ford H. T., Ormerod M. G. Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen. Br J Cancer. 1994 Dec;70(6):1211–1216. doi: 10.1038/bjc.1994.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gasparini G., Boracchi P., Verderio P., Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer. 1994 Jun 15;57(6):822–829. doi: 10.1002/ijc.2910570610. [DOI] [PubMed] [Google Scholar]
  7. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  8. Isola J. J., Helin H. J., Helle M. J., Kallioniemi O. P. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990 Mar 1;65(5):1180–1184. doi: 10.1002/1097-0142(19900301)65:5<1180::aid-cncr2820650525>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  9. Ljung B. M., Chew K., Deng G., Matsumura K., Waldman F., Smith H. Fine needle aspiration techniques for the characterization of breast cancers. Cancer. 1994 Aug 1;74(3 Suppl):1000–1005. doi: 10.1002/1097-0142(19940801)74:3+<1000::aid-cncr2820741505>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  10. Mansour E. G., Ravdin P. M., Dressler L. Prognostic factors in early breast carcinoma. Cancer. 1994 Jul 1;74(1 Suppl):381–400. doi: 10.1002/cncr.2820741326. [DOI] [PubMed] [Google Scholar]
  11. Michna H., Schneider M., Nishino Y., el Etreby M. F., McGuire W. L. Progesterone antagonists block the growth of experimental mammary tumors in G0/G1. Breast Cancer Res Treat. 1990 Dec;17(2):155–156. doi: 10.1007/BF01806296. [DOI] [PubMed] [Google Scholar]
  12. Onda K., Davis R. L., Shibuya M., Wilson C. B., Hoshino T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer. 1994 Oct 1;74(7):1921–1926. doi: 10.1002/1097-0142(19941001)74:7<1921::aid-cncr2820740716>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  13. Pich A., Ponti R., Valente G., Chiusa L., Geuna M., Novero D., Palestro G. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol. 1994 Jan;47(1):18–22. doi: 10.1136/jcp.47.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pinder S. E., Wencyk P., Sibbering D. M., Bell J. A., Elston C. W., Nicholson R., Robertson J. F., Blamey R. W., Ellis I. O. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995 Jan;71(1):146–149. doi: 10.1038/bjc.1995.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  16. Remvikos Y., Magdelénat H., Zajdela A. DNA flow cytometry applied to fine needle sampling of human breast cancer. Cancer. 1988 Apr 15;61(8):1629–1634. doi: 10.1002/1097-0142(19880415)61:8<1629::aid-cncr2820610821>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  17. Sahin A. A., Ro J., Ro J. Y., Blick M. B., el-Naggar A. K., Ordonez N. G., Fritsche H. A., Smith T. L., Hortobagyi G. N., Ayala A. G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 1;68(3):549–557. doi: 10.1002/1097-0142(19910801)68:3<549::aid-cncr2820680318>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  18. Shi S. R., Key M. E., Kalra K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. doi: 10.1177/39.6.1709656. [DOI] [PubMed] [Google Scholar]
  19. Silvestrini R., Daidone M. G., Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer. 1985 Oct 15;56(8):1982–1987. doi: 10.1002/1097-0142(19851015)56:8<1982::aid-cncr2820560816>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  20. Stål O., Dufmats M., Hatschek T., Carstensen J., Klintenberg C., Rutqvist L. E., Skoog L., Sullivan S., Wingren S., Nordenskjöld B. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol. 1993 Sep;11(9):1717–1722. doi: 10.1200/JCO.1993.11.9.1717. [DOI] [PubMed] [Google Scholar]
  21. Tubiana M., Pejovic M. H., Chavaudra N., Contesso G., Malaise E. P. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer. 1984 Apr 15;33(4):441–445. doi: 10.1002/ijc.2910330404. [DOI] [PubMed] [Google Scholar]
  22. Veronese S. M., Gambacorta M., Gottardi O., Scanzi F., Ferrari M., Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993 Jun 15;71(12):3926–3931. doi: 10.1002/1097-0142(19930615)71:12<3926::aid-cncr2820711221>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  23. Vielh P., Chevillard S., Mosseri V., Donatini B., Magdelenat H. Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol. 1990 Dec;94(6):681–686. doi: 10.1093/ajcp/94.6.681. [DOI] [PubMed] [Google Scholar]
  24. Walker R. A., Camplejohn R. S. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer. 1988 Mar;57(3):281–283. doi: 10.1038/bjc.1988.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wenger C. R., Beardslee S., Owens M. A., Pounds G., Oldaker T., Vendely P., Pandian M. R., Harrington D., Clark G. M., McGuire W. L. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 1993 Oct;28(1):9–20. doi: 10.1007/BF00666351. [DOI] [PubMed] [Google Scholar]
  26. Wintzer H. O., Zipfel I., Schulte-Mönting J., Hellerich U., von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991 Jan 15;67(2):421–428. doi: 10.1002/1097-0142(19910115)67:2<421::aid-cncr2820670217>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  27. van Dierendonck J. H., Keijzer R., van de Velde C. J., Cornelisse C. J. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res. 1989 Jun 1;49(11):2999–3006. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES